Woelfle, Tim http://orcid.org/0000-0001-6279-4158
Pless, Silvan http://orcid.org/0000-0002-9660-9077
Reyes, Oscar http://orcid.org/0000-0003-0169-297X
Wiencierz, Andrea http://orcid.org/0000-0001-8786-7915
Feinstein, Anthony http://orcid.org/0000-0002-0132-0909
Calabrese, Pasquale http://orcid.org/0000-0003-3347-5187
Gugleta, Konstantin http://orcid.org/0000-0002-3520-2791
Kappos, Ludwig http://orcid.org/0000-0003-4175-5509
Lorscheider, Johannes http://orcid.org/0000-0003-1100-2506
Naegelin, Yvonne http://orcid.org/0000-0002-1315-4100
Funding for this research was provided by:
Research Center for Clinical Neuroimmunology and Neuroscience Basel
University of Basel
Article History
Received: 26 May 2022
Revised: 21 July 2022
Accepted: 21 July 2022
First Online: 30 August 2022
Declarations
:
: The research activities of Tim Woelfle’s institution, RC2NB (Research Center for Clinical Neuroimmunology and Neuroscience Basel), are supported by the University Hospital and the University of Basel and by grants from Novartis and Roche. One of the main projects of RC2NB is the development of a new comprehensive MS Digital solution. Silvan Pless has nothing to disclose. Oscar Reyes is Senior Data Scientist of Healios AG. Andrea Wiencierz has nothing to disclose. Anthony Feinstein has nothing to disclose. Pasquale Calabrese has received honoraria for speaking at scientific meetings, serving at scientific advisory boards and consulting activities from: Abbvie, Actelion, Almirall, Bayer-Schering, Biogen Idec, Celgene, EISAI, Genzyme, Lundbeck, Merck Serono, Novartis, Pfizer, Teva, and Sanofi-Aventis. His research is also supported by the Swiss Multiple Sclerosis Society and the Swiss National Research Foundation. Konstantin Gugleta has nothing to disclose. Ludwig Kappos has received no personal compensation. His institution (University Hospital Basel/Foundation Clinical Neuroimmunology and Neuroscience Basel) has received the following exclusively for research support: steering committee, advisory board and consultancy fees (Abbvie, Actelion, AurigaVision AG, Biogen, Celgene, Desitin, Eli Lilly, EMD Serono, Genentech, Genzyme, Glaxo Smith Kline, Janssen, Japan Tobacco, Merck, Minoryx, Novartis, Roche, Sanofi, Santhera, Senda, Shionogi, Teva, and Wellmera; speaker fees (Celgene, Janssen, Merck, Novartis, and Roche); support for educational activities (Biogen, Desitin, Novartis, Sanofi and Teva); license fees for Neurostatus products; and grants (European Union, Innosuisse, Novartis, Roche Research Foundation, Swiss MS Society and Swiss National Research Foundation). Johannes Lorscheider’s institution has received research grants from Novartis, Biogen and Innosuisse as well as honoraria for advisory boards and/or speaking fees from Novartis, Roche and Teva. Yvonne Naegelin’s institution (University Hospital Basel) has received financial support for lectures from Teva and Celgene and grant support from Innosuisse (Swiss Innovation Agency). The research activities of RC2NB (Research Center for Clinical Neuroimmunology and Neuroscience Basel) are supported by the University Hospital and the University of Basel and by grants from Novartis and Roche. One of the main projects of RC2NB is the development of a new comprehensive MS Digital solution.